TEP With 68-DOTANOC in Gastroenteropancreatic Neuroendocrine Tumors
Status:
Completed
Trial end date:
2016-05-01
Target enrollment:
Participant gender:
Summary
Evaluation of the diagnostic performance of PET / CT with 68Ga-DOTANOC in
Gastroenteropancreatic Neuroendocrine Tumors with comparison with other techniques used in
routine clinical practice (octreoscan ® ; multiphase SPECT / CT, MRI or endoscopy).
Therapeutic impact and safety of PET / CT with 68Ga-DOTANOC will also be assessed. Expected
results are a confirmation of the superiority of 68Ga-PET DOTANOC versus scintigraphy
octreoscan ®, with a potential impact on the therapeutic management of patients.